- Home
- MIST vs BOLD Comparison
MIST vs BOLD Comparison
Compare MIST & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIST
- BOLD
- Stock Information
- Founded
- MIST 2003
- BOLD 2018
- Country
- MIST Canada
- BOLD United States
- Employees
- MIST N/A
- BOLD N/A
- Industry
- MIST Biotechnology: Pharmaceutical Preparations
- BOLD
- Sector
- MIST Health Care
- BOLD
- Exchange
- MIST Nasdaq
- BOLD Nasdaq
- Market Cap
- MIST 217.5M
- BOLD 24.4M
- IPO Year
- MIST N/A
- BOLD 2024
- Fundamental
- Price
- MIST $1.60
- BOLD $1.21
- Analyst Decision
- MIST Strong Buy
- BOLD Buy
- Analyst Count
- MIST 2
- BOLD 3
- Target Price
- MIST $7.50
- BOLD $4.00
- AVG Volume (30 Days)
- MIST 2.6M
- BOLD 279.6K
- Earning Date
- MIST 08-07-2025
- BOLD 08-11-2025
- Dividend Yield
- MIST N/A
- BOLD N/A
- EPS Growth
- MIST N/A
- BOLD N/A
- EPS
- MIST N/A
- BOLD N/A
- Revenue
- MIST N/A
- BOLD N/A
- Revenue This Year
- MIST N/A
- BOLD N/A
- Revenue Next Year
- MIST N/A
- BOLD N/A
- P/E Ratio
- MIST N/A
- BOLD N/A
- Revenue Growth
- MIST N/A
- BOLD N/A
- 52 Week Low
- MIST $0.63
- BOLD $1.00
- 52 Week High
- MIST $2.75
- BOLD $4.72
- Technical
- Relative Strength Index (RSI)
- MIST 46.03
- BOLD N/A
- Support Level
- MIST $1.36
- BOLD N/A
- Resistance Level
- MIST $1.73
- BOLD N/A
- Average True Range (ATR)
- MIST 0.18
- BOLD 0.00
- MACD
- MIST -0.07
- BOLD 0.00
- Stochastic Oscillator
- MIST 23.75
- BOLD 0.00
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.